Johnson & Johnson JNJ
NYSE JNJ
$266.48 -0.60 (-0.23%)
As of: Sep 10, 2026 · 12:39 PM EDT

Johnson & Johnson (JNJ) Non-Current Debt (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Non-Current Debt came in at $37.3 billion in Q2 2026, down 4.82% year-over-year from $39.2 billion in Q2 2025, and little changed quarter-over-quarter from $37.5 billion in Q1 2026.

Analysis

Johnson & Johnson (JNJ) Non-Current Debt (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Non-Current Debt across 18 years of filings, most recently posting $37.3 billion for Q2 2026.

  • In Q2 2026, Non-Current Debt fell 4.82% year-over-year to $37.3 billion; the TTM figure through Jun 2026 stood at $37.3 billion (down 4.82% YoY), while the FY2025 annual figure was $39.4 billion, up 21.72% from the prior year.
  • Non-Current Debt came in at $37.3 billion for Q2 2026 at Johnson & Johnson, roughly flat from $37.5 billion in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $39.4 billion in Q4 2025 to a low of $25.1 billion in Q1 2024.
  • Average Non-Current Debt over 5 years is $32.6 billion, with a median of $32.1 billion recorded in 2022.
  • Year-over-year, Non-Current Debt slipped 28.19% in 2024 and surged 52.92% in 2025.
  • Over 5 years, Non-Current Debt stood at $27.6 billion in 2022, then retreated by 0.92% to $27.4 billion in 2023, then increased by 18.46% to $32.4 billion in 2024, then increased by 21.72% to $39.4 billion in 2025, then slipped by 5.31% to $37.3 billion in 2026.
  • Per Business Quant data, the three most recent Non-Current Debt figures were $37.3 billion in Q2 2026, $37.5 billion in Q1 2026, and $39.4 billion in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Johnson & Johnson 641.39 Bn 620.63 Bn 17.26 Bn 37.34 Bn
2 AbbVie 445.66 Bn 439.09 Bn 12.70 Bn 62.48 Bn
3 Merck 357.45 Bn 350.31 Bn 12.21 Bn 51.08 Bn
4 Novartis Ag 267.58 Bn 259.89 Bn 11.24 Bn -
5 Pfizer 156.75 Bn 145.05 Bn 10.94 Bn 60.50 Bn
6 Sanofi 52.14 Bn 44.75 Bn 10.79 Bn 17.02 Bn
7 Revolution Medicines 42.91 Bn 42.91 Bn - -
8 Incyte 24.62 Bn 20.08 Bn 1.57 Bn -
9 United Therapeutics 21.28 Bn 18.62 Bn 683.80 Mn -
10 Neurocrine Biosciences 15.81 Bn 15.42 Bn 935.80 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 28, 2026 37.34 Bn
Mar 29, 2026 37.53 Bn
Dec 28, 2025 39.44 Bn
Sep 28, 2025 39.41 Bn
Jun 29, 2025 39.24 Bn
Mar 30, 2025 38.36 Bn
Dec 29, 2024 32.40 Bn
Sep 29, 2024 31.29 Bn
Jun 30, 2024 31.64 Bn
Mar 31, 2024 25.08 Bn
Dec 31, 2023 27.35 Bn
Oct 1, 2023 26.05 Bn
Jul 2, 2023 33.90 Bn
Apr 2, 2023 34.93 Bn
Jan 1, 2023 28.44 Bn
Oct 2, 2022 27.60 Bn
Jul 3, 2022 28.29 Bn
Apr 3, 2022 28.85 Bn
Jan 2, 2022 32.12 Bn
Oct 3, 2021 30.13 Bn